James F Burke1, Eve A Kerr2, Ryan J McCammon2, Rob Holleman2, Kenneth M Langa2, Brian C Callaghan2. 1. From the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI. jamesbur@med.umich.edu. 2. From the Department of Neurology (J.F.B., B.C.C.), Department of Internal Medicine (E.A.K., R.J.M., K.M.L.), Institute for Healthcare Policy and Innovation (J.F.B., E.A.K., K.M.L., B.C.C.), and Institute for Social Research (K.M.L.), University of Michigan, Ann Arbor; and Neurology Section (J.F.B., B.C.C.) and Center for Clinical Management and Research (E.A.K., R.H., K.M.L.), VA Ann Arbor Healthcare System, MI.
Abstract
OBJECTIVE: To inform initiatives to reduce overuse, we compared neuroimaging appropriateness in a large Medicare cohort with a Department of Veterans Affairs (VA) cohort. METHODS: Separate retrospective cohorts were established in Medicare and in VA for headache and neuropathy from 2004 to 2011. The Medicare cohorts included all patients enrolled in the Health and Retirement Study (HRS) with linked Medicare claims (HRS-Medicare; n = 1,244 for headache and 998 for neuropathy). The VA cohorts included all patients receiving services in the VA (n = 93,755 for headache and 183,642 for neuropathy). Inclusion criteria were age over 65 years and an outpatient visit for incident neuropathy or a primary headache. Neuroimaging use was measured with Current Procedural Terminology codes and potential overuse was defined using published criteria for use with administrative data. Increasingly specific appropriateness criteria excluded nontarget conditions for which neuroimaging may be appropriate. RESULTS: For both peripheral neuropathy and headache, potentially inappropriate imaging was more common in HRS-Medicare compared with the VA. Forty-nine percentage of all headache patients received neuroimaging in HRS-Medicare compared with 22.1% in the VA (p < 0.001) and differences persist when analyzing more specific definitions of overuse. A total of 23.7% of all HRS-Medicare incident neuropathy patients received neuroimaging compared with 9.0% in the VA (p < 0.001), and the difference persisted after excluding nontarget conditions. CONCLUSIONS: Overuse of neuroimaging is likely less common in the VA than in a Medicare population. Better understanding the reasons for the more selective use of neuroimaging in the VA could help inform future initiatives to reduce overuse of diagnostic testing.
OBJECTIVE: To inform initiatives to reduce overuse, we compared neuroimaging appropriateness in a large Medicare cohort with a Department of Veterans Affairs (VA) cohort. METHODS: Separate retrospective cohorts were established in Medicare and in VA for headache and neuropathy from 2004 to 2011. The Medicare cohorts included all patients enrolled in the Health and Retirement Study (HRS) with linked Medicare claims (HRS-Medicare; n = 1,244 for headache and 998 for neuropathy). The VA cohorts included all patients receiving services in the VA (n = 93,755 for headache and 183,642 for neuropathy). Inclusion criteria were age over 65 years and an outpatient visit for incident neuropathy or a primary headache. Neuroimaging use was measured with Current Procedural Terminology codes and potential overuse was defined using published criteria for use with administrative data. Increasingly specific appropriateness criteria excluded nontarget conditions for which neuroimaging may be appropriate. RESULTS: For both peripheral neuropathy and headache, potentially inappropriate imaging was more common in HRS-Medicare compared with the VA. Forty-nine percentage of all headache patients received neuroimaging in HRS-Medicare compared with 22.1% in the VA (p < 0.001) and differences persist when analyzing more specific definitions of overuse. A total of 23.7% of all HRS-Medicare incident neuropathy patients received neuroimaging compared with 9.0% in the VA (p < 0.001), and the difference persisted after excluding nontarget conditions. CONCLUSIONS: Overuse of neuroimaging is likely less common in the VA than in a Medicare population. Better understanding the reasons for the more selective use of neuroimaging in the VA could help inform future initiatives to reduce overuse of diagnostic testing.
Authors: Brian C Callaghan; Kevin A Kerber; Lynda L Lisabeth; Lewis B Morgenstern; Ruth Longoria; Ann Rodgers; Paxton Longwell; Eva L Feldman Journal: JAMA Neurol Date: 2014-09 Impact factor: 18.302
Authors: Ruth Ann Marrie; Bo Nancy Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard Journal: Neuroepidemiology Date: 2012-10-24 Impact factor: 3.282
Authors: J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D N Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner Journal: Neurology Date: 2008-12-03 Impact factor: 9.910
Authors: James Henderson; Zachary Bouck; Rob Holleman; Cherry Chu; Mandi L Klamerus; Robin Santiago; R Sacha Bhatia; Eve A Kerr Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Evan L Reynolds; James F Burke; Lacey Evans; Faiz I Syed; Eric Liao; Remy Lobo; Wade Cooper; Larry Charleston; Brian C Callaghan Journal: Headache Date: 2022-01 Impact factor: 5.311
Authors: Thomas R Radomski; Robert Feldman; Yan Huang; Florentina E Sileanu; Carolyn T Thorpe; Joshua M Thorpe; Michael J Fine; Walid F Gellad Journal: JAMA Netw Open Date: 2020-09-01